Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01321463 · ClinicalTrials.gov registry record · Phase 2
Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) Taking Salmeterol Xinafoate/Fluticasone Propionate Combination
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 377
- Enrollment target
NCT01321463 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 377 participants.
The verdict
NCT01321463, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 377 participants
- Enrollment target
Study Summary
PH-797804 is an oral ant-inflammatory drug that may reduce the inflammation that is associated with COPD. PH-797804 will be dosed to patients with COPD to evaluate its potential safety and efficacy profile in COPD.
Interventions
- DRUG Placebo
- DRUG PH-797804
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 377 participants |
| Start Date | 2011-05 |
| Est. Completion | 2012-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01321463
The ClinicalTrials.gov registry entry for NCT01321463 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 377 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01321463 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01321463 about?
NCT01321463 is a clinical study titled "Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) Taking Salmeterol Xinafoate/Fluticasone Propionate Combination". PH-797804 is an oral ant-inflammatory drug that may reduce the inflammation that is associated with COPD. PH-797804 will be dosed to patients with COPD to evaluate its potential safety and efficacy profile in COPD.
What is the current status of trial NCT01321463?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 377 participants. The study started on 2011-05. Estimated completion is 2012-06.
What interventions are being tested in trial NCT01321463?
The interventions under investigation include: Placebo (DRUG), PH-797804 (DRUG).
Who is sponsoring clinical trial NCT01321463?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.